Conference Day 2, May 23

CONFERENCE DAY 1
CONFERENCE DAY 2

9:00 am Check-In & Coffee

9:25 am Chair’s Opening Remarks

  • Saso Cemerski Executive Director & Head of Immune Engagers, AstraZeneca

Evolution & Innovation: Navigating Recent Approvals, Charting Future Directions, & Brainstorming to Reduce Patient Burden

9:30 am Mapping the Past, Present, & Future of Cell Engager Therapies

Synopsis

  • Revisit the recent development landscape of cell engagers within 7 recent approvals
  • Understand which mechanisms, modalities, and formats are demonstrating promise towards developing the next approved cell engagers
  • Reimagine future directions for cell engagers for both mono and combination therapies

10:00 am Panel Discussion: Brainstorming Combinations With CART, DDR, Cytokine-Based Therapies & Other Cell Engagers

Synopsis

  • Discuss potential benefits and risks of combining cell engagers with alternate cancer therapies for personalized treatment strategies
  • How can cell engager combinations be developed to reduce potential relapse while reducing the patient burden of treatment?
  • Can these combinations mitigate T cell exhaustion to improve efficacy across cancer types and reduce patient burden?

11:00 am Morning Refreshments & Networking

Pursuing the Next Generation of Cell Engagers to Create Robust Immune Responses

12:00 pm Developing a Highly Specific ImmTAC Against PIWIL1, a Promising Novel Colorectal Cancer Target

  • Annelise Vuidepot Chief Technology Officer - Head of Pipeline and Platform Research site Head, Immunocore Ltd

Synopsis

  • Exploring a program case study accelerating towards clinic
  • An overview of target selection processes and engineering to ensure specific and minimize off target activity

12:30 pm Accessing Intracellular Cancer Targets via Potent & Specific TCR Mimetic (TCRm)-Based T Cell Engagers

Synopsis

  • Previously unreachable target classes amenable to TCRm-based T Cell engagers
  • Differences and similarities between soluble TCR and TCRm-based T cell engager approaches
  • Unique challenges and opportunities in developing TCRm-based T Cell Engagers

1:00 pm Lunch & Networking

Moving Beyond T-Cells & Unlocking More Immune Cells to Take Action & Drive Tumor Killing

2:00 pm Developing Ex Vivo Precision Gene Engineered B Cell Medicines to Create Sustainable Anti-Tumor Activity & Overcome Pharmacokinetic Shortcomings of BiTEs

Synopsis

  • Exploring BiTE-expressing BECMs associated with reduced tumor burden in patientderived xenograft models
  • Achieving clinically meaningful serum levels of BiTE

2:30 pm Exploiting Phagocytosis With Macrophage Engagers to Enhance Tumor Killing in Solid Tumors

  • Hongtao Lu Co-Founder and Chief Scientific Officer, Elpiscience

Synopsis

  • Advantage of inducing cancer death and clearance by implementing macrophage phagocytosis as compared to T cell engagers
  • Explore the development challenges of macrophage engagers in comparison to alternate cell types
  • Utilize innate immune cells for improved targeting of cancers in solid tumors

Exploring Co-Stimulation & Integrated Immune Signaling During Cell Engager Development to Induce Long-Lasting Immune Memory

3:00 pm Mastering Immune Potency Through Integration of Co-Stimulation for Improved Immune Cell Activity to Enhance Cytotoxicity

Synopsis

  • Improving T cell activity beyond initial activation through integrating co-stimulation into biologics development for improved memory response and reduce risk of relapse or resistance
  • Enhancing cytotoxicity and synergy with checkpoint inhibitors to sustain adaptability to cancer types
  • What are the right co-stimulatory responses to activate solid tumor treatment?

3:30 pm Chair’s Closing Remarks

  • Saso Cemerski Executive Director & Head of Immune Engagers, AstraZeneca
CONFERENCE DAY 1
SPEAKER FACULTY